{"id":"W2563154257","doi":"10.1182/blood.v126.23.2736.2736","title":"Five-Year Survival Data Demonstrating Durable Responses from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Brentuximab vedotin; Medicine; Internal medicine; Chemotherapy regimen; Oncology; Refractory (planetary science); Clinical endpoint; Lymphoma; Chemotherapy; Surgery; CD30; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002744136,0.0005448218,0.001068251,0.0002433616,0.0002498325,0.0007508794,0.0003925148,0.0005471138,0.001655057],"category_scores_gemma":[0.001681704,0.0002169719,0.0008257008,0.0002954812,0.0002235331,0.0004846192,0.0003243224,0.001312038,0.0003092395],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000468169,"about_ca_system_score_gemma":0.0004840326,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003088052,"about_ca_topic_score_gemma":0.000827814,"domain_scores_codex":[0.9993458,0.0003213068,0.00006487448,0.0001010917,0.0000931155,0.00007365874],"domain_scores_gemma":[0.9985687,0.0004289276,0.0003716861,0.0001416437,0.0001605471,0.000328539],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4740025,0.01542498,0.1155878,0.002536609,0.006883917,0.0009546185,0.0009406695,0.003813556,0.07169658,0.0003773785,0.01247718,0.2953043],"study_design_scores_gemma":[0.1657761,0.4462244,0.346726,0.0002878311,0.005864188,0.002419855,0.0002579671,0.002667942,0.01052021,0.0004152786,0.01874114,0.00009906851],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9874679,0.008246626,0.0004674115,0.0003003571,0.00006989064,0.0005028912,0.001414003,0.00003102852,0.001499795],"genre_scores_gemma":[0.993417,0.00184399,0.0003590385,0.0004769496,0.00006903085,0.0002690588,0.002990616,0.000009763626,0.0005644948],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002744136,"threshold_uncertainty_score":0.01451254,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0458306916567111,"score_gpt":0.3027311426956338,"score_spread":0.2569004510389227,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}